| 14/06/22 | 07:00:07 | 14 Jun 2022 | | Potential role of invasive cellular protrusions |
| 30/05/22 | 07:00:07 | 30 May 2022 | | Partnership with major United States urology group |
| 27/05/22 | 07:00:07 | 27 May 2022 | | Molecular characterisation of CTCs |
| 25/05/22 | 16:35:20 | 25 May 2022 | | Price Monitoring Extension |
| 25/05/22 | 12:30:35 | 25 May 2022 | | ANGLE receives FDA clearance for Parsortix |
| 20/05/22 | 07:00:08 | 20 May 2022 | | Prostate Cancer UK funds new study using Parsortix |
| 28/04/22 | 07:00:12 | 28 Apr 2022 | | Preliminary Results |
| 20/04/22 | 07:00:05 | 20 Apr 2022 | | Notice of Preliminary Results and Webcast |
| 14/04/22 | 07:00:06 | 14 Apr 2022 | | Poster on Parsortix system presented at AACR 2022 |
| 01/04/22 | 07:00:10 | 1 Apr 2022 | | Identifying drug targets in cancer metastasis |
| 29/03/22 | 07:00:11 | 29 Mar 2022 | | Rapid information on patient response to therapies |
| 25/03/22 | 07:00:07 | 25 Mar 2022 | | Identifying therapeutic targets in TNBC patients |
| 15/03/22 | 07:00:07 | 15 Mar 2022 | | Update on laboratory accreditation |
| 09/03/22 | 16:41:33 | 9 Mar 2022 | | Second Price Monitoring Extn |
| 09/03/22 | 16:36:10 | 9 Mar 2022 | | Price Monitoring Extension |
| 02/03/22 | 18:29:01 | 2 Mar 2022 | | Holding(s) in Company |
| 18/02/22 | 17:13:01 | 18 Feb 2022 | | Issue of Equity |
| 21/01/22 | 07:00:16 | 21 Jan 2022 | | Potential in immunotherapy treatment selection |
| 17/01/22 | 07:00:08 | 17 Jan 2022 | | Concordance of Parsortix with tissue biopsy |
| 13/01/22 | 07:00:05 | 13 Jan 2022 | | Update on lab accreditation and ovarian study |
| 10/01/22 | 07:00:10 | 10 Jan 2022 | | Insight into drug resistance in NSCLC |
| 22/12/21 | 18:29:15 | 22 Dec 2021 | | Issue of Equity |
| 01/12/21 | 18:11:04 | 1 Dec 2021 | | Issue of Equity |
| 01/12/21 | 07:00:10 | 1 Dec 2021 | | Parsortix in RNA analysis of CTCs as tool in NSCLC |
| 26/11/21 | 17:33:54 | 26 Nov 2021 | | Issue of Equity |
| 17/11/21 | 10:32:30 | 17 Nov 2021 | | Issue of Equity |
| 15/11/21 | 07:00:07 | 15 Nov 2021 | | Issue of LTIP Options and Share Options |
| 15/11/21 | 07:00:06 | 15 Nov 2021 | | Appointment of Chief Medical Officer |
| 12/11/21 | 17:51:20 | 12 Nov 2021 | | Issue of Equity |
| 12/11/21 | 07:00:03 | 12 Nov 2021 | | Participation at Jefferies healthcare conference |
| 11/11/21 | 07:00:04 | 11 Nov 2021 | | Parsortix system showcased at NCRI Festival |
| 10/11/21 | 17:40:00 | 10 Nov 2021 | | Issue of Equity |
| 02/11/21 | 07:00:05 | 2 Nov 2021 | | Change of Adviser |
| 21/10/21 | 17:25:01 | 21 Oct 2021 | | Issue of Equity |
| 15/10/21 | 17:45:17 | 15 Oct 2021 | | Issue of Equity |
| 30/09/21 | 16:02:39 | 30 Sept 2021 | | Issue of Equity |
| 30/09/21 | 07:00:10 | 30 Sept 2021 | | Interim Results |
| 27/09/21 | 07:00:10 | 27 Sept 2021 | | Parsortix demonstrates ability to isolate CTCs |
| 22/09/21 | 07:00:05 | 22 Sept 2021 | | Study shows use of Parsortix to assess PD-L1 |
| 20/09/21 | 07:00:09 | 20 Sept 2021 | | Parsortix enables gene expression analysis in mPCa |
| 07/09/21 | 07:00:04 | 7 Sept 2021 | | Notice of Interim Results and Webcast |
| 24/08/21 | 07:00:03 | 24 Aug 2021 | | Director/PDMR Shareholding |
